Premium
Cerebrospinal fluid levels of S‐100b protein and neuron‐specific enolase in chronic inflammatory demyelinating polyneuropathy
Author(s) -
Nagamatsu M.,
Mokuno K.,
Sugimura K.,
Kiyosawa K.,
Aoki S.,
Takahashi A.,
Kato K.
Publication year - 1995
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1995.tb00450.x
Subject(s) - chronic inflammatory demyelinating polyneuropathy , enolase , medicine , cerebrospinal fluid , polyneuropathy , gastroenterology , pathology , immunology , antibody , immunohistochemistry
We measured the cerebrospinal fluid (CSF) concentrations of S‐100b protein (S‐100b) and neuron‐specific enolase (NSE) using enzyme immunoassay methods in 15 patients with chronic inflammatory demyelinating polyneuropathy (CIDP), other three patients with chronic neuropathy with demyelination, eight patients with various axonal neuropathies (AN), and 46 controls, to investigate the clinical usefulness of the determination of these two specific proteins in these neuropathies. S‐100b levels were elevated (>the mean ± 2 SD levels of controls) in the majority of patients with clinically progressing CIDP (9/11), but not in the patients with AN (0/8). In parallel with the clinical improvement, S‐100b levels were normalized in patients with CIDP (10/10), though total protein levels in the CSF still remained high in some of these patients (5/10). Elevation of NSE levels were seldom seen in clinically worsening patients with CIDP (1/11) or AN (1/8). Thus our results indicated that the level of S‐100b in the CSF may be useful to assess the activity of actual disease process in CIDP.